NovoCure Ltd (NVCR)
Sector: Healthcare
Industry: Surgical & Medical Instruments & Apparatus
Country: JE
Exchange: NASDAQ
Market cap: $1.94B
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Latest financial period: June 30, 2026
Filed with the SEC: July 23, 2026
Estimated earnings date: October 29, 2026
Profit #1358 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 6.4% | 5.7% | 6.7% | 6.6% |
Growth #272 of 1484 companies
Payout #1117 of 1484 companies
Safety #1306 of 1484 companies
Price #1402 of 1484 companies
